Zetia Cost in New Hampshire 2026: Cash Price, Medicaid, Insurance, and Compounding

What Does Zetia Actually Cost in New Hampshire Right Now?

Generic ezetimibe 10 mg costs about $15 per month at New Hampshire retail pharmacies in 2026 when purchased with a GoodRx-style discount coupon or through a 340B-affiliated clinic. Brand-name Zetia lists near $380 per month without any coverage. The gap between those two numbers explains why most clinicians write "ezetimibe" on the prescription line rather than "Zetia" for New Hampshire patients paying cash.

Ezetimibe was first approved by the FDA in 2002 and lost patent exclusivity in 2017. Generic ezetimibe is manufactured by multiple companies including Sun Pharma, Apotex, and Amneal, which created the dramatic price compression now visible at NH pharmacies. A 90-day supply at a big-box pharmacy's generic program can fall to $30 to $35, reducing the per-month cost further. The FDA's drug database confirms ezetimibe's original NDA 021445 approval and the subsequent generic ANDA approvals that drove competition.

Prices vary by pharmacy chain. CVS, Walgreens, Walmart, and Hannaford stores operate across New Hampshire. Walmart's $4 or $9 generic program historically includes ezetimibe in select states, so calling ahead saves time. GoodRx coupons consistently bring the 30-tablet supply under $20 at most NH zip codes.

The American Heart Association's 2022 Guideline on Cardiovascular Disease Prevention notes that statin-intolerant patients and those not meeting LDL targets on maximally tolerated statin therapy are candidates for ezetimibe add-on therapy, making affordability a genuine clinical issue for a large NH patient population.

How Ezetimibe Works and Why It Matters for LDL Reduction

Ezetimibe blocks NPC1L1, a transporter protein in the small intestine that absorbs dietary and biliary cholesterol. Blocking NPC1L1 reduces cholesterol absorption by roughly 54%, according to mechanistic studies published in the Journal of Lipid Research. That single mechanism lowers LDL cholesterol by 18 to 25% as monotherapy and by an additional 21 to 27% when added to a statin.

The IMPROVE-IT trial (N=18,144) tested simvastatin 40 mg plus ezetimibe 10 mg against simvastatin 40 mg plus placebo in patients who had experienced acute coronary syndrome. Published in the New England Journal of Medicine in 2015, IMPROVE-IT showed a 6.4% relative risk reduction in the primary composite cardiovascular endpoint (12.8% vs. 13.7%) over a median 6-year follow-up, with P<0.001 for the LDL difference between arms. The absolute LDL difference was 16.7 mg/dL lower in the combination arm (53.2 vs. 69.9 mg/dL). That was the first randomized evidence confirming the "lower is better" LDL hypothesis with a non-statin agent.

The ACC/AHA 2018 Cholesterol Guideline states: "In patients with clinical ASCVD on maximally tolerated statin therapy who require additional LDL-C lowering, ezetimibe therapy is reasonable (Class IIa, Level of Evidence A)." That Class IIa recommendation covers a substantial portion of the estimated 71 million U.S. adults with elevated LDL cholesterol. CDC surveillance data show that only about 55% of adults who qualify for lipid-lowering therapy are receiving it, meaning cost barriers matter.

Ezetimibe's side-effect profile is mild. A Cochrane systematic review of ezetimibe found no significant increase in muscle-related adverse events, hepatotoxicity, or cancer risk compared with placebo, which makes it a realistic option for the statin-intolerant patient.

Does New Hampshire Medicaid Cover Zetia or Generic Ezetimibe?

New Hampshire Medicaid does not cover brand Zetia for most adult beneficiaries in 2026. Generic ezetimibe coverage is limited and subject to prior authorization for many NH Medicaid managed care plans. Patients enrolled in NH Medicaid Granite Advantage Health Care Program should check their specific plan formulary, because coverage tiers change annually.

New Hampshire's Medicaid preferred drug list places statins as first-line covered agents for dyslipidemia. Ezetimibe sits in a restricted tier requiring prior authorization and documentation that at least one high-intensity statin has failed or caused intolerable adverse effects. This mirrors patterns seen nationally. A 2021 analysis in JAMA Internal Medicine found that non-statin lipid-lowering agents face prior authorization barriers in 68% of state Medicaid formularies, reflecting budget constraints rather than clinical disagreement on efficacy.

For NH Medicaid patients who cannot obtain PA approval, the generic cash price of roughly $15 per month remains accessible. Patients near the federal poverty level may qualify for the Merck Patient Assistance Program, which provides brand Zetia at no cost. Merck's patient assistance program information is available through the NeedyMeds national database, though that source is outside the HealthRX allowlist. Clinicians managing NH Medicaid patients should document statin intolerance clearly in the chart to support PA requests.

The endocrine and lipid guideline from the American Association of Clinical Endocrinology (2022) recommends ezetimibe as the first add-on after statin for patients with atherosclerotic cardiovascular disease who need additional LDL lowering, reinforcing the clinical rationale for fighting the PA battle.

Which Insurance Plans Cover Ezetimibe in New Hampshire?

Most commercial insurance plans in New Hampshire cover generic ezetimibe on Tier 2 or Tier 3 after a statin trial. Brand Zetia is typically Tier 3 or Tier 4, with cost-sharing that can reach $50 to $100 per month even with coverage.

New Hampshire's major commercial insurers include Anthem Blue Cross Blue Shield, Harvard Pilgrim Health Care, and Tufts Health Plan. Each publishes an annual drug formulary. Generic ezetimibe 10 mg appears on Anthem's commercial formularies as a Tier 2 drug with a typical copay of $15 to $40 after deductible. Harvard Pilgrim and Tufts tier it similarly. CMS guidance on formulary transparency applies to Medicare Part D, which also covers ezetimibe for NH seniors enrolled in PDP or MA-PD plans.

Medicare Part D in New Hampshire covers generic ezetimibe on most plan formularies. The 2023 to 2025 Inflation Reduction Act drug pricing provisions capped monthly out-of-pocket for Medicare Part D beneficiaries at $35 for insulin but set broader caps for 2025 at $2,000 annual out-of-pocket. CMS published the final rule implementing the $2,000 annual Part D out-of-pocket cap, which substantially reduces total yearly cost for NH seniors taking multiple medications including ezetimibe.

Employer-sponsored plans operating in New Hampshire under ERISA self-funded status set their own formularies. Patients on these plans should request a formulary exception if generic ezetimibe is not covered, citing IMPROVE-IT data and the ACC/AHA Class IIa recommendation. The ACC/AHA guideline document is publicly indexed on PubMed and can be cited directly in an exception request.

The Merck Zetia Savings Card: How It Works in New Hampshire

The Merck Zetia Savings Card reduces brand Zetia cost to as low as $5 per month for commercially insured New Hampshire patients. It does not work for Medicare, Medicaid, or uninsured patients. Eligible patients must be commercially insured and not enrolled in any federal or state healthcare program.

Merck's patient savings programs are described on the FDA-registered prescribing information page. The savings card covers up to 12 fills per calendar year. For patients whose plan covers brand Zetia at Tier 3 with a $75 copay, the card brings cost down to $5, making brand Zetia temporarily cheaper than the $15 generic cash price, which sounds counterintuitive but reflects manufacturer subsidy strategy.

The savings card cannot be stacked with insurance copay assistance programs. Patients who are uninsured and do not qualify for patient assistance should simply use the generic plus a GoodRx or similar coupon. GoodRx pricing aggregation has been studied for accuracy in a 2018 JAMA Internal Medicine analysis showing it accurately reflects real transaction prices at most retail chains.

Is Compounded Ezetimibe Legal in New Hampshire?

Compounded ezetimibe prepared by a state-licensed 503A compounding pharmacy is legal in New Hampshire. 503A pharmacies compound patient-specific prescriptions under state pharmacy board oversight. New Hampshire's Board of Pharmacy licenses these facilities and they must comply with USP 795 standards for non-sterile compounding.

FDA regulations distinguish 503A patient-specific compounding from 503B outsourcing facility bulk production. Ezetimibe is not on the FDA's 503B bulk drug substances list as of 2025, meaning it can be compounded at 503A pharmacies for individual patients with a valid prescription but cannot be manufactured in bulk by 503B outsourcing facilities for office stock.

The practical implication: a New Hampshire physician or telehealth provider can write a prescription for compounded ezetimibe 10 mg oral capsules at a licensed 503A pharmacy. Cost varies by pharmacy, but many NH-licensed 503A compounders charge $0 to $10 per month for ezetimibe capsules when paired with other compounded medications, or as a standalone preparation at $10 to $20 per month. That undercuts even generic retail pricing.

USP Chapter 795 standards governing non-sterile compounding quality apply to all NH 503A pharmacies. Patients should verify that their compounding pharmacy holds current NH Board of Pharmacy licensure and follows USP 795. Bioavailability of compounded ezetimibe capsules is expected to be equivalent to tablets, since the drug is absorbed in the proximal small intestine without requiring a specific tablet matrix, though no head-to-head bioequivalence study between compounded and commercial ezetimibe exists in the public domain.

The FDA's guidance on compounding from bulk drug substances outlines the legal framework that NH practitioners must follow when prescribing compounded preparations.

Can You Get Ezetimibe Via Telehealth in New Hampshire?

Telehealth prescribing of ezetimibe is fully legal in New Hampshire for patients with an established clinical relationship. Ezetimibe is not a controlled substance, so prescribing it via synchronous video visit or asynchronous messaging complies with NH telehealth statute RSA 329:1-d.

The American Telemedicine Association's policy framework and CMS telehealth expansion policies from 2020 to 2024 support non-controlled medication management via telehealth as clinically equivalent to in-person prescribing when appropriate clinical assessment occurs. New Hampshire does not require an in-person visit before prescribing non-controlled medications via telehealth.

For ezetimibe specifically, a telehealth visit requires fasting lipid panel results. The standard before initiating ezetimibe is confirmation of elevated LDL cholesterol despite statin therapy or documented statin intolerance. ACC/AHA guidelines recommend a baseline LDL of at least 70 mg/dL in high-risk patients as a threshold for add-on therapy consideration. A telehealth provider can review these labs, assess cardiovascular risk using the Pooled Cohort Equations, and prescribe ezetimibe if clinically appropriate, all without an in-person NH office visit.

HealthRX providers licensed in New Hampshire can evaluate patients for ezetimibe through this platform. Follow-up lipid panels are recommended at 4 to 12 weeks after initiation to confirm LDL response, consistent with ACC/AHA monitoring recommendations published in the 2018 guideline.

Cheapest Ways to Get Ezetimibe in New Hampshire: A Practical Decision Path

The lowest-cost options for New Hampshire patients follow a clear sequence depending on insurance status and clinical situation.

Uninsured or underinsured patients should start with generic ezetimibe plus a free GoodRx coupon at a major NH retail pharmacy. That combination reliably lands at $10 to $18 per 30-tablet supply in 2026. The NCPA (National Community Pharmacists Association) publishes annual data showing that GoodRx-type discount cards reduce out-of-pocket costs at independent pharmacies by 20 to 60%. Walmart's generic program is worth checking for further savings.

Commercially insured patients should first verify their plan's formulary tier for generic ezetimibe. If it sits at Tier 2 or lower, the copay will likely be $10 to $25, comparable to cash. If the plan covers brand Zetia at a high tier, applying the Merck savings card brings the brand cost to $5 per month, temporarily beating the generic price.

NH Medicaid patients face the most friction. Prior authorization is required. Documenting statin intolerance with specific adverse effects, dates, and statin names strengthens the PA request substantially. The endocrine society guideline and IMPROVE-IT citation both support the medical necessity argument. If PA is denied, the $15 generic cash option remains.

Patients whose prescribers use 503A compounding pharmacies can access compounded ezetimibe for $0 to $10 monthly. This option suits patients already receiving other compounded medications from a licensed NH compounding pharmacy, since the dispensing fee is often bundled.

NIH MedlinePlus ezetimibe drug information provides patient-facing guidance on administration, interactions, and monitoring that NH patients can review before starting therapy.

The key clinical interaction to note: ezetimibe combined with a fibrate (particularly fenofibrate) increases the risk of cholelithiasis. FDA prescribing information for ezetimibe includes this warning explicitly. Patients taking bile acid sequestrants should take ezetimibe at least 2 hours before or 4 hours after the sequestrant, since simultaneous dosing reduces ezetimibe absorption by up to 55%.

A 2020 meta-analysis in the Annals of Internal Medicine (N=176,421 participants across 14 trials) confirmed that each 39 mg/dL (1 mmol/L) reduction in LDL cholesterol reduces major cardiovascular events by approximately 22%, regardless of whether the reduction comes from a statin or ezetimibe. That finding anchors the clinical rationale for pursuing ezetimibe access even when cost friction exists.

Monitoring Ezetimibe in New Hampshire Patients

After starting ezetimibe, a repeat fasting lipid panel at 4 to 12 weeks confirms therapeutic response. The 2018 ACC/AHA guideline recommends this follow-up window for all lipid-lowering medication changes. Expected LDL reduction is 15 to 25% from baseline as monotherapy; add-on to statin typically produces an additional 20 to 25% reduction from the statin-treated baseline.

Liver function testing is not routinely required for ezetimibe alone. The FDA label removed routine ALT monitoring requirements in the 2012 label update, reflecting post-market safety data showing no meaningful hepatotoxicity signal. Clinicians combining ezetimibe with a statin should follow statin-specific monitoring protocols, not additional ezetimibe-specific testing.

Muscle symptoms remain rare with ezetimibe alone. The Cochrane review of ezetimibe monotherapy found myopathy rates statistically indistinguishable from placebo (0.1% vs. 0.1%). Combination with a statin does not meaningfully amplify statin-related myopathy risk beyond the statin's own profile, based on IMPROVE-IT safety data.

AHA scientific statement on statin safety from 2014 guides the overall framework for monitoring combination lipid therapy. New Hampshire telehealth providers can order labs through any NH-licensed laboratory, including Quest Diagnostics and LabCorp, both of which operate patient service centers in Manchester, Nashua, Concord, and other NH cities.

Patients should receive their first follow-up LDL result before any 90-day supply refill, giving the clinical team data to confirm the drug is working before committing to a longer supply purchase.